Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salmeterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 18/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 17/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | FPR3 | P25089 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salmeterol SCHEMBL29393289 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL4767 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL4768 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL4452108 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL4450046 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL7176067 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL28889602 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL29266779 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL6152211 | 0.98 | ADRB2 (0.96) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL4454918 | 0.98 | ADRB2 (0.96) | ADRB2ADRB1ADRB3KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057696-B | Hydroxynitrile lyase mutant and application thereof in synthesis of (R) -salmeterol | 华东理工大学 | 2022-11-11 | — | — | CN | claimed |
| EP-4676481-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4665321-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | Atrogi AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| EP-4651867-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | Atrogi AB (SE) | 2025-11-26 | — | — | EP | disclosed |
| US-20250262170-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND BETA 3-ADRENERGIC RECEPTOR AGONISTS, AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2025-08-21 | — | — | US | disclosed |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4511014-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND BETA 3-ADRENERGIC RECEPTOR AGONISTS, AND MEDICAL USES THEREOF | Atrogi AB (SE) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024184408-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024170727-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | ATROGI AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024153813-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | ATROGI AB (SE) | 2024-07-25 | — | — | WO | disclosed |
| WO-2023097697-A1 | METHOD FOR SYNTHESIZING (1R)-1-(2,2-DIMETHYL-4H-1,3-BENZODIOXIN-6-YL)OXAZOLIDIN-2-ONE | 广东莱佛士制药技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-20230149327-A1 | Use of Salmeterol as an Anti-Coronaviral Agent | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-18 | — | — | US | disclosed |
| US-11590089-B2 | Beta-2 selective adrenergic receptor agonists | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2023279315-A1 | USE OF 2\"-O-RHAMNOSYL ICARISIDE II IN MUSCLE REPAIR AND REGENERATION | 中国科学院深圳先进技术研究院 | 2023-01-12 | — | — | WO | disclosed |
| CN-111057696-B | Hydroxynitrile lyase mutant and application thereof in synthesis of (R) -salmeterol | 华东理工大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-111057696-B | Hydroxynitrile lyase mutant and application thereof in synthesis of (R) -salmeterol | 华东理工大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-111057696-B | Hydroxynitrile lyase mutant and application thereof in synthesis of (R) -salmeterol | 华东理工大学 | 2022-11-11 | — | — | CN | disclosed |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-27 | — | — | US | disclosed |
| US-11464862-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114057713-A | Method for synthesizing (R) -salmeterol intermediate | 广东莱佛士制药技术有限公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590089-B2 | Beta-2 selective adrenergic receptor agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRB3 5/4885 |
| US-20250262170-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND BETA 3-ADRENERGIC RECEPTOR AGONISTS, AND MEDICAL USES THEREOF | ADRB2, ADRB3, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 2/4885 |
| US-11464862-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | DSP, DSC1, SAE1 | ADRB2 1196/4885ADRB1 1315/4885ADRB3 1548/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | ADRB2 40/4885ADRB1 25/4885ADRB3 29/4885 |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CRH, HRH1, IL5 | ADRB2 40/4885ADRB1 25/4885ADRB3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.